INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India

/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from...

Related Keywords

Mexico ,Philippines ,United States ,India ,Brazil ,China ,Colombia ,South Korea ,America ,Ben Matone ,Jeff Richardson ,Kaneka Eurogentec ,J Joseph Kim ,Walter Reed Army Institute Of Research ,National Cancer Institute ,National Institute Of Allergy ,Plumbline Life Sciences ,Melinda Gates Foundation ,Coalition For Epidemic Preparedness Innovations ,Astrazeneca ,Advaccine Biopharmaceuticals Suzhou Co Ltd ,India Central Drugs Standard Control Organization ,Nuclear Defense ,Defense Consortium ,Parker Institute For Cancer Immunotherapy ,International Vaccine Institute ,Defense Health Agency ,National Institutes Of Health ,Nuclear Defense Department Of ,Health Affairs ,Apollobio Corporation ,Vaccines Trial Network ,Office Of The ,University Of Pennsylvania ,Wistar Institute ,Central Drugs Standard Control Organization ,Drug Controller General ,Latin America ,Defense Joint Program Executive Office ,Assistant Secretary ,Defense Health ,Interim Phase ,Advaccine Biopharmaceuticals ,Epidemic Preparedness Innovations ,Defense Advanced Research Projects ,Joint Program Executive Office ,Trial Network ,National Institutes ,National Institute ,Infectious Diseases ,Ology Bioservices ,Parker Institute ,Richter Helm Biologics ,Thermo Fisher Scientific ,Walter Reed Army Institute ,Inovio Pharmaceuticals ,Nc ,